Loader
We have noticed an unusual activity from your IP 199.16.157.181 and blocked access to this
We have noticed an unusual activity from your IP 199.16.157.181 and blocked access to this
Molecular MRD after induction chemotherapy identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.Patients achieving M
A new medication is offering some ALS patients more hope than ever. It’s actually slowing the disease down in some people like Jessica Morris.
Fundraise smarter not harder. Raise more money effortlessly. With just a few clicks, you can get started quickly. Products can be purchased online and sent…
The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry registry powered by NORD platform.
Aliya Khan, MD, at McMaster University, highlights the best practices to diagnose and treat tumor-induced osteomalacia (TIO)
The mission of the Smith-Magenis Research Foundation is to support research to improve the knowledge and understanding of Smith-Magenis Syndrome (SMS) so that viable therapeutic…
Brahm Goldstein, MD, Vice President, R&D, Hematology at CSL Behring, discusses HEMGENIX, a pivotal gene therapy for hemophilia B.
Wenyu Huang, MD, PhD highlights the latest clinical research about acromegaly, a rare endocrine disorder, presented at ENDO 2023.
We have noticed an unusual activity from your IP 199.16.157.183 and blocked access to this
Alaa Hamed, MD, Global Head of Medical Affairs Rare Diseases at Sanofi, discusses the importance of rare disease registries.